Thermo Fisher Scientific Change in Contract Assets and Liabilities, Net remained flat by 0.0% to $93.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 131.5%, from $40.50M to $93.75M. Over 4 years (FY 2021 to FY 2025), Change in Contract Assets and Liabilities, Net shows an upward trend with a 14.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase in net liabilities (deferred revenue) provides a cash boost, signaling strong future demand or subscription-based business models.
This represents the net change in assets and liabilities arising from contracts with customers, such as deferred revenue...
Common in companies with service-heavy or long-term contract business models; comparable to deferred revenue changes at peers.
tmo_change_in_contract_assets_and_liabilities_net| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | -$221.00M | $354.00M | -$252.00M | $162.00M | $375.00M |
| YoY Change | — | +260.2% | -171.2% | +164.3% | +131.5% |